PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Paltusotine→

Paltusotine PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
2172870-89-0
Molecular formula
C27H22F2N4O
Molecular weight
456.5 g/mol
Drug class
Oral non-peptide somatostatin receptor 2 (SSTR2) agonistacromegaly therapy
Mechanism of action
Activates somatostatin receptor 2 on pituitary somatotroph cells, reducing growth hormone secretion and downstream circulating insulin-like growth factor-1 (IGF-1).
Indications / reported uses
  • Treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option under the US PALSONIFY indication (approved 25 September 2025)

Sources: US FDA — PALSONIFY approval and indication · FDA Orphan Drug database — Paltusotine · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Paltusotine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Paltusotine Permitted Daily Exposure (PDE) report (the Paltusotine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Paltusotine Occupational Exposure Limit (OEL) report (the Paltusotine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.